NZ548513A - Methods of producing peptides/proteins in plants and peptides/proteins produced thereby - Google Patents

Methods of producing peptides/proteins in plants and peptides/proteins produced thereby

Info

Publication number
NZ548513A
NZ548513A NZ548513A NZ54851305A NZ548513A NZ 548513 A NZ548513 A NZ 548513A NZ 548513 A NZ548513 A NZ 548513A NZ 54851305 A NZ54851305 A NZ 54851305A NZ 548513 A NZ548513 A NZ 548513A
Authority
NZ
New Zealand
Prior art keywords
hydroxyproline
biologically active
protein
growth hormone
hyp
Prior art date
Application number
NZ548513A
Other languages
English (en)
Inventor
Marcia J Kieliszewski
Jianfeng Xu
John Kopchick
Shigeru Okada
Original Assignee
Univ Ohio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio filed Critical Univ Ohio
Publication of NZ548513A publication Critical patent/NZ548513A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
NZ548513A 2004-01-14 2005-01-14 Methods of producing peptides/proteins in plants and peptides/proteins produced thereby NZ548513A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53648604P 2004-01-14 2004-01-14
US58202704P 2004-06-22 2004-06-22
US60256204P 2004-08-18 2004-08-18
PCT/US2005/001160 WO2005069845A2 (en) 2004-01-14 2005-01-14 Methods of producing peptides/proteins in plants and peptides/proteins produced thereby

Publications (1)

Publication Number Publication Date
NZ548513A true NZ548513A (en) 2010-05-28

Family

ID=34812077

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ548513A NZ548513A (en) 2004-01-14 2005-01-14 Methods of producing peptides/proteins in plants and peptides/proteins produced thereby

Country Status (9)

Country Link
US (7) US20060026719A1 (enExample)
EP (2) EP2133427B1 (enExample)
JP (2) JP2007521807A (enExample)
AU (1) AU2005206885B2 (enExample)
CA (1) CA2553257A1 (enExample)
IL (1) IL176781A0 (enExample)
MX (1) MXPA06008126A (enExample)
NZ (1) NZ548513A (enExample)
WO (1) WO2005069845A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563687B2 (en) 1997-07-21 2013-10-22 Ohio University Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US9006410B2 (en) 2004-01-14 2015-04-14 Ohio University Nucleic acid for plant expression of a fusion protein comprising hydroxyproline O-glycosylation glycomodule

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20070212703A1 (en) * 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
TWI321052B (en) * 2005-11-08 2010-03-01 Univ Kaohsiung Medical Composition for treating cancer cells and preparation method thereof
AU2006337137B2 (en) * 2005-12-29 2012-06-14 Tersera Therapeutics Llc Multicyclic amino acid derivatives and methods of their use
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
EP2084285A4 (en) * 2006-07-10 2010-01-13 Univ Ohio COEXPRESSION OF PROLIN HYDROXYLASES TO FACILITATE HYP-GLYCOSYLATION OF PROTEINS EXPRESSED AND SEPARATED IN PLANT CELLS
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
EP2195338B1 (en) * 2007-10-01 2013-12-25 Pharmaessentia Corp. N-terminal modified interferon-alpha
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
AU2010258898B8 (en) * 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
WO2011059828A1 (en) * 2009-10-29 2011-05-19 University Of Kansas Methods of producing and purifying proteins
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
CN107496932A (zh) 2012-02-27 2017-12-22 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
WO2015130963A2 (en) * 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
KR101652953B1 (ko) 2016-01-15 2016-08-31 (주)넥스젠바이오텍 열 안정성이 증가한 인간성장호르몬 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2019210377A1 (en) * 2018-04-30 2019-11-07 L'oreal Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor
WO2019215280A1 (en) * 2018-05-09 2019-11-14 Greenaltech, S.L Gycomodule motifs and uses thereof
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
EP3820497A4 (en) 2018-07-11 2022-03-23 Ohio University Peptide-based inhibitors of growth hormone action and methods of use thereof
CN111802241B (zh) * 2020-07-24 2022-11-08 海南广陵高科实业有限公司 一种高抗性水稻的育种方法
KR102723629B1 (ko) * 2020-09-25 2024-10-30 주식회사 프로앱텍 기능성폴리펩티드 변이체의 컨쥬게이트 및 그 용도
WO2022065913A1 (ko) 2020-09-25 2022-03-31 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
AU2024246108A1 (en) 2023-03-24 2025-09-25 Gat Biosciences, S.L. Modified antibodies and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3664925A (en) * 1970-02-20 1972-05-23 Martin Sonenberg Clinically active bovine growth hormone fraction
US4056520A (en) * 1972-03-31 1977-11-01 Research Corporation Clinically active bovine growth hormone fraction
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US5034322A (en) * 1983-01-17 1991-07-23 Monsanto Company Chimeric genes suitable for expression in plant cells
US5352605A (en) * 1983-01-17 1994-10-04 Monsanto Company Chimeric genes for transforming plant cells using viral promoters
NL8300698A (nl) 1983-02-24 1984-09-17 Univ Leiden Werkwijze voor het inbouwen van vreemd dna in het genoom van tweezaadlobbige planten; agrobacterium tumefaciens bacterien en werkwijze voor het produceren daarvan; planten en plantecellen met gewijzigde genetische eigenschappen; werkwijze voor het bereiden van chemische en/of farmaceutische produkten.
US4478827A (en) * 1983-05-09 1984-10-23 The General Hospital Corporation Renin inhibitors
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US6774283B1 (en) * 1985-07-29 2004-08-10 Calgene Llc Molecular farming
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
IL90146A (en) * 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US6680426B2 (en) * 1991-01-07 2004-01-20 Auburn University Genetic engineering of plant chloroplasts
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
ATE189526T1 (de) 1988-10-28 2000-02-15 Genentech Inc Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5501967A (en) 1989-07-26 1996-03-26 Mogen International, N.V./Rijksuniversiteit Te Leiden Process for the site-directed integration of DNA into the genome of plants
NL8901932A (nl) * 1989-07-26 1991-02-18 Mogen Int Produktie van heterologe eiwitten in planten of plantecellen.
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US6583115B1 (en) 1989-10-12 2003-06-24 Ohio University/Edison Biotechnology Institute Methods for treating acromegaly and giantism with growth hormone antagonists
US6787336B1 (en) * 1989-10-12 2004-09-07 Ohio University/Edison Biotechnology Institute DNA encoding growth hormone antagonists
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5989894A (en) * 1990-04-20 1999-11-23 University Of Wyoming Isolated DNA coding for spider silk protein, a replicable vector and a transformed cell containing the DNA
EP0550629A1 (en) 1990-08-17 1993-07-14 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US5506107A (en) 1991-05-10 1996-04-09 Genentech, Inc. Selecting ligand agonists and antagonists
WO1992020713A1 (en) 1991-05-15 1992-11-26 The University Of Melbourne Proline rich protein from nicotiana alata
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5474925A (en) * 1991-12-19 1995-12-12 Agracetus, Inc. Immobilized proteins in cotton fiber
US6225080B1 (en) * 1992-03-23 2001-05-01 George R. Uhl Mu-subtype opioid receptor
US5352596A (en) * 1992-09-11 1994-10-04 The United States Of America As Represented By The Secretary Of Agriculture Pseudorabies virus deletion mutants involving the EPO and LLT genes
AU682340B2 (en) * 1993-01-28 1997-10-02 Regents Of The University Of California, The TATA-binding protein associated factors, nucleic acids encoding TAFs, and methods of use
JPH0762038B2 (ja) * 1993-08-19 1995-07-05 ユニヴァーシティー オブ ユータ グリコシル化インシュリン及びそれを含む糖尿病治療剤
US5646029A (en) * 1993-12-03 1997-07-08 Cooperative Research Centre For Industrial Plant Biopolymers Plant arabinogalactan protein (AGP) genes
WO1995019799A1 (en) * 1994-01-21 1995-07-27 Agracetus, Inc. Gas driven gene delivery instrument
US5733771A (en) * 1994-03-14 1998-03-31 University Of Wyoming cDNAs encoding minor ampullate spider silk proteins
US6080560A (en) * 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5695971A (en) * 1995-04-07 1997-12-09 Amresco Phage-cosmid hybrid vector, open cos DNA fragments, their method of use, and process of production
US5723755A (en) * 1995-05-16 1998-03-03 Francis E. Lefaivre Large scale production of human or animal proteins using plant bioreactors
WO1997004122A1 (en) * 1995-07-20 1997-02-06 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
DE851925T1 (de) 1995-09-21 2003-08-14 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
AR006928A1 (es) * 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
US5821089A (en) * 1996-06-03 1998-10-13 Gruskin; Elliott A. Amino acid modified polypeptides
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6548642B1 (en) 1997-07-21 2003-04-15 Ohio University Synthetic genes for plant gums
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US5994099A (en) * 1997-12-31 1999-11-30 The University Of Wyoming Extremely elastic spider silk protein and DNA coding therefor
US6037456A (en) * 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
US20030167531A1 (en) * 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
ATE475714T1 (de) * 1998-12-09 2010-08-15 Phyton Holdings Llc Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild
US6210950B1 (en) * 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
WO2001016339A1 (en) * 1999-08-27 2001-03-08 University Of Guelph Use of arabinogalactan protein fusion constructs in a method of expressing proteins and peptides in plants
IL150314A0 (en) 1999-12-30 2002-12-01 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
US20020127652A1 (en) * 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US20020174453A1 (en) * 2001-04-18 2002-11-21 Henry Daniell Production of antibodies in transgenic plastids
US20030041353A1 (en) * 2001-04-18 2003-02-27 Henry Daniell Mutiple gene expression for engineering novel pathways and hyperexpression of foreign proteins in plants
US20020162135A1 (en) * 2001-04-18 2002-10-31 Henry Daniell Expression of antimicrobial peptide via the plastid genome to control phytopathogenic bacteria
WO2001075132A2 (en) 2000-04-03 2001-10-11 Monsanto Technology Llc Method for producing authentic cytokines in plants
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
EP1334442A2 (en) 2000-11-06 2003-08-13 Thrasos, Inc. Computer method and apparatus for classifying objects
US6987172B2 (en) * 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US7173113B2 (en) * 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
EP1624847B1 (en) * 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
JP2005087172A (ja) * 2003-09-19 2005-04-07 Institute Of Physical & Chemical Research アラビノガラクタン様ｏ−結合型糖鎖付加モチーフ
NZ548513A (en) 2004-01-14 2010-05-28 Univ Ohio Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
WO2005110015A2 (en) 2004-04-19 2005-11-24 Ohio University Cross-linkable glycoproteins and methods of making the same
WO2006035442A2 (en) 2004-09-29 2006-04-06 Collplant Ltd. Collagen producing plants and methods of generating and using same
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
EP2084285A4 (en) 2006-07-10 2010-01-13 Univ Ohio COEXPRESSION OF PROLIN HYDROXYLASES TO FACILITATE HYP-GLYCOSYLATION OF PROTEINS EXPRESSED AND SEPARATED IN PLANT CELLS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563687B2 (en) 1997-07-21 2013-10-22 Ohio University Synthetic genes for plant gums and other hydroxyproline rich glycoproteins
US8871468B2 (en) 1997-07-21 2014-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US9006410B2 (en) 2004-01-14 2015-04-14 Ohio University Nucleic acid for plant expression of a fusion protein comprising hydroxyproline O-glycosylation glycomodule
US8623812B2 (en) 2004-04-19 2014-01-07 Ohio University Cross-linkable glycoproteins and methods of making the same

Also Published As

Publication number Publication date
US20110230404A1 (en) 2011-09-22
US20060026719A1 (en) 2006-02-02
MXPA06008126A (es) 2008-02-14
WO2005069845A3 (en) 2006-07-13
JP2007521807A (ja) 2007-08-09
AU2005206885B2 (en) 2012-02-02
US8962811B2 (en) 2015-02-24
US9006410B2 (en) 2015-04-14
EP2133427A1 (en) 2009-12-16
US20100029548A1 (en) 2010-02-04
AU2005206885A1 (en) 2005-08-04
US20140024806A1 (en) 2014-01-23
US20100028993A1 (en) 2010-02-04
EP1711533A2 (en) 2006-10-18
CA2553257A1 (en) 2005-08-04
EP1711533A4 (en) 2008-02-27
US20060148680A1 (en) 2006-07-06
JP2013208114A (ja) 2013-10-10
WO2005069845A2 (en) 2005-08-04
EP2133427B1 (en) 2013-12-11
EP1711533B1 (en) 2013-12-11
HK1139180A1 (en) 2010-09-10
IL176781A0 (en) 2006-10-31
US20110217766A1 (en) 2011-09-08

Similar Documents

Publication Publication Date Title
US9006410B2 (en) Nucleic acid for plant expression of a fusion protein comprising hydroxyproline O-glycosylation glycomodule
Xu et al. High‐yields and extended serum half‐life of human interferon α2b expressed in tobacco cells as arabinogalactan‐protein fusions
Xu et al. Human growth hormone expressed in tobacco cells as an arabinogalactan-protein fusion glycoprotein has a prolonged serum life
US11911443B2 (en) Fusion proteins with extended serum half life
DE60221051T2 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
US7595294B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
US20150158920A1 (en) Transgenic plants expressing cobalamin binding proteins
US20080214440A1 (en) Vasoactive intestinal polypeptide compositions
US20070293429A1 (en) Vasoactive Intestinal Polypeptide Compositions
HK1139180B (en) Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
HK1105004A (en) Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
CN1930189A (zh) 在植物中生产肽/蛋白质的方法以及用该方法生产的肽/蛋白质
WO2025099208A1 (en) Recombinant insulin precursor
OA20681A (en) N-terminal extension sequence for expression of recombinant therapeutic peptides.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JAN 2016 BY COMPUTER PACKAGES INC

Effective date: 20150318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20151218

LAPS Patent lapsed